Mori M - Search Results

1

Effect of calcitriol on prostate-specific antigen in vitro and in humans.

Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K. Beer TM, et al. Among authors: mori m. Clin Cancer Res. 2006 May 1;12(9):2812-6. doi: 10.1158/1078-0432.CCR-05-2310. Clin Cancer Res. 2006. PMID: 16675575

2

Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma.

Beer TM, Eilers KM, Garzotto M, Hsieh YC, Mori M. Beer TM, et al. Among authors: mori m. Cancer. 2004 Feb 15;100(4):758-63. doi: 10.1002/cncr.20024. Cancer. 2004. PMID: 14770432 Free article. Clinical Trial.

3

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. Fromme EK, et al. Among authors: mori m. J Clin Oncol. 2004 Sep 1;22(17):3485-90. doi: 10.1200/JCO.2004.03.025. J Clin Oncol. 2004. PMID: 15337796

4

Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen.

Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, Garzotto M. Panagiotou I, et al. Among authors: mori m. Oncology. 2004;67(3-4):194-202. doi: 10.1159/000081317. Oncology. 2004. PMID: 15557778

5

Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies.

Garzotto M, Park Y, Mongoue-Tchokote S, Bledsoe J, Peters L, Blank BH, Austin D, Beer TM, Mori M. Garzotto M, et al. Among authors: mori m. Cancer. 2005 Nov 1;104(9):1911-7. doi: 10.1002/cncr.21420. Cancer. 2005. PMID: 16130139 Free article.

6

Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.

Spurgeon SE, Mongoue-Tchokote S, Collins L, Priest R, Hsieh YC, Peters LM, Beer TM, Mori M, Garzotto M. Spurgeon SE, et al. Among authors: mori m. Urology. 2007 May;69(5):931-5. doi: 10.1016/j.urology.2007.01.075. Urology. 2007. PMID: 17482937

7

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.

Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN; ASCENT Investigators. Beer TM, et al. Among authors: mori m. Cancer. 2008 Jun;112(11):2377-83. doi: 10.1002/cncr.23461. Cancer. 2008. PMID: 18428198 Free article. Clinical Trial.

8

Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.

Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Garzotto M, et al. Among authors: mori m. Cancer. 2003 Oct 1;98(7):1417-22. doi: 10.1002/cncr.11668. Cancer. 2003. PMID: 14508828 Free article.

9

Improved detection of prostate cancer using classification and regression tree analysis.

Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, Klein T, Mori M. Garzotto M, et al. Among authors: mori m. J Clin Oncol. 2005 Jul 1;23(19):4322-9. doi: 10.1200/JCO.2005.11.136. Epub 2005 Mar 21. J Clin Oncol. 2005. PMID: 15781880

10

Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.

Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M. Janoff DM, et al. Among authors: mori m. BJU Int. 2005 Sep;96(4):503-7. doi: 10.1111/j.1464-410X.2005.05674.x. BJU Int. 2005. PMID: 16104900

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,991 results

Search Page

Filters